Pulmocide is a UK-based biotechnology company developing a leading range of first-in-class inhaled anti-infectives for the targeted treatment of life-threatening lung infections.
Location: United Kingdom, England, London
Total raised: $174M
Investors 7
| Date | Name | Website |
| - | Jeito Capi... | jeito.life |
| - | F-Prime Ca... | fprimecapi... |
| - | Adjuvant C... | adjuvantca... |
| 23.01.2023 | Vivo Capit... | vivocapita... |
| - | SV Health ... | svhealthin... |
| - | Eight Road... | eightroads... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.12.2022 | - | $52M | - |
| 27.05.2021 | Series C | $92M | Jeito Capi... |
| 21.03.2017 | Series B | $30M | - |
Mentions in press and media 14
| Date | Title | Description |
| 15.04.2024 | Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole | Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients Discontinuations due to drug-related adverse events and drug-drug interactions lower in th... |
| 06.12.2022 | Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | - |
| 06.12.2022 | Pulmocide Ltd - Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | Strong support from high-quality new and existing investors provides capital for opelconazole development and pre-commercialization activities well beyond ongoing registration studies LONDON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pulmocide... |
| 06.12.2021 | CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transplant Recipients | - |
| 27.05.2021 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suf... |
| 27.05.2021 | Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide | Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide Jeito selects Pulmocide as its fourth investment since launching the fundPulmocide is a late-stage biopharma company focused on the development of novel tr... |
| 27.05.2021 | IP GROUP PLC IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| 27.05.2021 | IP : Pulmocide Ltd - Raises $92 million in a Series C financing to fund registration program for PC945 | Pulmocide Ltd., ('the Company') a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 million in an oversubscr... |
| 27.05.2021 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 | London, UK, 27May2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced it has raised $92 ... |
| 27.05.2021 | Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 | - |
Show more